Статии с изисквания за обществен достъп - Funda Meric-BernstamНаучете повече
Не е налице никъде: 24
Преглед
Targeting the PI3K pathway in cancer: are we making headway?
F Janku, TA Yap, F Meric-Bernstam
Nature reviews Clinical oncology 15 (5), 273-291, 2018
Изисквания: US National Institutes of Health
Преглед
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
AM Gonzalez-Angulo, K Stemke-Hale, SL Palla, M Carey, R Agarwal, ...
Clinical Cancer Research 15 (7), 2472-2478, 2009
Изисквания: US National Institutes of Health
Преглед
Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas
F Meric-Bernstam, RF Sweis, FS Hodi, WA Messersmith, RHI Andtbacka, ...
Clinical cancer research 28 (4), 677-688, 2022
Изисквания: US National Institutes of Health
Преглед
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
Изисквания: US National Institutes of Health, Cancer Prevention Research Institute of …
Преглед
Overcoming implementation challenges of personalized cancer therapy
F Meric-Bernstam, GB Mills
Nature reviews Clinical oncology 9 (9), 542-548, 2012
Изисквания: US National Institutes of Health
Преглед
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis
PF McAuliffe, F Meric-Bernstam, GB Mills, AM Gonzalez-Angulo
Clinical breast cancer 10, S59-S65, 2010
Изисквания: US National Institutes of Health
Преглед
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
K Raghav, JM Loree, JS Morris, MJ Overman, R Yu, F Meric-Bernstam, ...
JCO Precision Oncology 3, 1-13, 2019
Изисквания: US National Institutes of Health, National Institute for Health Research, UK
Преглед
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience
JC Yao, AT Phan, V Jehl, G Shah, F Meric-Bernstam
Cancer research 73 (5), 1449-1453, 2013
Изисквания: US National Institutes of Health
Преглед
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients
AS Caudle, M Yi, KE Hoffman, EA Mittendorf, GV Babiera, RF Hwang, ...
Annals of surgical oncology 21, 60-65, 2014
Изисквания: US National Institutes of Health
Преглед
Regulation and localization of ribosomal protein S6 kinase 1 isoforms
D Kim, A Akcakanat, G Singh, C Sharma, F Meric-Bernstam
Growth factors 27 (1), 12-21, 2009
Изисквания: US National Institutes of Health
Преглед
Molecular tumour boards—current and future considerations for precision oncology
AM Tsimberidou, M Kahle, HH Vo, MA Baysal, A Johnson, ...
Nature Reviews Clinical Oncology 20 (12), 843-863, 2023
Изисквания: US National Institutes of Health
Преглед
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes
N Parinyanitikul, X Lei, M Chavez-MacGregor, S Liu, EA Mittendorf, ...
Clinical breast cancer 15 (2), 153-160, 2015
Изисквания: US National Institutes of Health, Susan G. Komen
Преглед
Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial
F Meric-Bernstam, NM Tannir, O Iliopoulos, RJ Lee, ML Telli, AC Fan, ...
Clinical Cancer Research 28 (8), 1540-1548, 2022
Изисквания: US National Institutes of Health
Преглед
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
MA Bilen, A Patel, KR Hess, J Munoz, NL Busaidy, JJ Wheler, F Janku, ...
Cancer chemotherapy and pharmacology 78, 167-171, 2016
Изисквания: US National Institutes of Health
Преглед
Precision medicine in oncology—toward the integrated targeting of somatic and germline genomic aberrations
TA Yap, A Johnson, F Meric-Bernstam
JAMA oncology 7 (4), 507-509, 2021
Изисквания: US National Institutes of Health, Cancer Prevention Research Institute of …
Преглед
OncotypeDX recurrence score does not predict nodal burden in clinically node negative breast cancer patients
SE Tevis, R Bassett, I Bedrosian, CH Barcenas, DM Black, AS Caudle, ...
Annals of surgical oncology 26, 815-820, 2019
Изисквания: US National Institutes of Health
Преглед
Pembrolizumab in patients with refractory cutaneous squamous cell carcinoma: a phase II trial
R Ferrarotto, LG Sousa, Y Qing, D Kaya, B Stephen, D Jain, D Bell, S Pant, ...
Advances in Therapy 38 (8), 4581-4591, 2021
Изисквания: US National Institutes of Health
Преглед
To dissect or not to dissect: can we predict the presence of four or more axillary lymph node metastases in postmenopausal women with clinically node-negative breast cancer?
C Farley, R Bassett, F Meric-Bernstam, I Bedrosian, A Caudle, ...
Annals of surgical oncology 30 (13), 8327-8334, 2023
Изисквания: US National Institutes of Health
Преглед
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection
X Le, FO Gleber-Netto, ML Rubin, Y Qing, R Du, M Kies, ...
Clinical Cancer Research 28 (13), 2796-2806, 2022
Изисквания: US National Institutes of Health
Преглед
Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control …
ML LeNoue-Newton, SC Chen, T Stricker, DM Hyman, N Blauvelt, ...
Clinical Cancer Research 28 (10), 2118-2130, 2022
Изисквания: US National Institutes of Health, Cancer Prevention Research Institute of …
Информацията за публикацията и осигуреното финансиране се определя автоматично от компютърна програма